Thompson, Jeffrey C.
Scholes, Dylan G.
Carpenter, Erica L. http://orcid.org/0000-0002-0735-3605
Aggarwal, Charu
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08 CA234335)
Article History
Received: 24 April 2023
Revised: 5 September 2023
Accepted: 14 September 2023
First Online: 3 October 2023
Competing interests
: JCT reports a consulting or advisory role for AstraZeneca and research funding to institution from Delfi Diagnostics and Incyte. ELC reports a consulting or advisory role for Bristol Myers Squibb, honoraria from AstraZeneca, Imedex, Guardant Health and Dartmouth Health and research funding to institution from Merck, Janssen, Becton Dickinson, NCCN, United Health Group, Parker Institute for Cancer Immunotherapy, AstraZeneca, Chip Diagnostics, C2i genomics, and Tempus. CA reports a consulting or advisory role for Genentech, Lilly, Celgene, Merck Sharp & Dohme, AstraZeneca, Blueprint Genetics, Shionogi, Daiichi Sankyo/Astra Zeneca, Sanofi/ Regeneron, Eisai, BeiGene, Turning Point Therapeutics, Pfizer, Janssen, Boehringer Ingelheim and research funding to institution from Genentech/Roche, Incyte, Macrogenics, Merck Sharp & Dohme, and AstraZeneca. DGS reports no competing interests.